文献リスト

1）Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation. 2013; 127: e6-e245

2）Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996; 334: 1349-55

3）The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991; 325: 293-302

4）Moss AJ, Zareba W, Hall WJ, et al; Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002; 346: 877-83

5）Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005; 352: 1539-49

6）Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009; 119: e391-479

7）Loh JC, Creaser J, Rourke DA, et al. Temporal trends in treatment and outcomes for advanced heart failure with reduced ejection fraction from 1993-2010: findings from a university referral center. Circ Heart Fail. 2013; 6: 411-9

8）Pepper GS, Lee RW. Sympathetic activation in heart failure and its treatment with beta-blockade. Arch Intern Med. 1999; 159: 225-34

9）Regitz V, Leuchs B, Bossaller C, et al. Myocardial catecholamine concentrations in dilated cardiomyopathy and heart failure of different origins. Eur Heart J. 1991; 12: S171-4

10）Piacentino III V, Weber CR, Chen X, et al. Cellular basis of abnormal calcium transients of failing human ventricular myocytes. Circ Res. 2003; 92: 651-8

11）Simpson P, McGrath A, Savion S. Myocyte hypertrophy in neonatal rat heart cultures and its regulation by serum and by catecholamines. Circ Res. 1982; 51: 787-801

12）Weber KT, Sun Y, Campbell SE. Structural remodelling of the heart by fibrous tissue: role of circulating hormones and locally produced peptides. Eur Heart J. 1995; 16 Suppl N: 12-8

13）Olivetti G, Abbi R, Quaini F, et al. Apoptosis in the failing human heart. N Engl J Med. 1997; 336: 1131-41

14）Communal C, Singh K, Pimentel DR, et al. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. Circulation. 1998; 98: 1329-34

15）Olshansky B, Sabbah HN, Hauptman PJ, et al. Parasympathetic nervous system and heart failure. Pathophysiology and potential implications for therapy. Circulation. 2008; 118: 863-71

16）Bibevski S, Dunlap ME. Evidence for impaired vagus nerve activity in heart failure. Heart Fail Rev. 2011; 16: 129-35

17）Fox K, Borer JS, Camm AJ, et al. Resting heart rate in cardiovascular disease. J Am Coll Cardiol. 2007; 50: 823-30

18）Sandercock GR, Brodie DA. The role of heart rate variability in prognosis for different modes of death in chronic heart failure. Pacing Clin Electrophysiol. 2006; 29: 892-904

19）Li W, Olshansky B. Inflammatory cytokines and nitric oxide in heart failure and potential modulation by vagus nerve stimulation. Heart Fail Rev. 2011; 16: 137-45

20）Tracey KJ. Physiology and immunology of the cholinergic antiinflammatory pathway. J Clin Invest. 2007; 117: 289-96

21）Tracey KJ. The inflammatory reflex. Nature. 2002; 420: 853-9

22）Oke SL, Tracey KJ. From CNI-1493 to the immunological homunculus: physiology of the inflammatory reflex. J Leukoc Biol. 2008; 83: 512-7

23）Wang H, Yu M, Ochani M, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature. 2003; 421: 384-8

24）de Jonge WJ, van der Zanden EP, The FO, et al. Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway. Nat Immunol. 2005; 6: 844-51

25）Wang H, Liao H, Ochani M, et al. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med. 2004; 10: 1216-21

26）Borovikova LV, Ivanova S, Zhang M, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature. 2000; 405: 458-62

27）Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990; 223: 236-41

28）Torre-Amione G, Kapadia S, Lee J, et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation. 1996; 93: 704-11

29）Torre-Amione G, Kapadia S, Benedict C, et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 1996; 27: 1201-6

30）Testa M, Yeh M, Lee P, et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol. 1996; 28: 964-71

31）Aukrust P, Ueland T, Muller F, et al. Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation. 1998; 97: 1136-43

32）Aukrust P, Ueland T, Lien E, et al. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1999; 83: 376-82

33）Deswal A, Petersen NJ, Feldman AM, et al. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation. 2001; 103: 2055-9

34）Blum A, Miller H. Pathophysiological role of cytokines in congestive heart failure. Annu Rev Med. 2001; 52: 15-27

35）Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res. 2002; 91: 988-98

36）Finkel MS, Oddis CV, Jacob TD, et al. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science. 1992; 157: 387-9

37）Yokoyama T, Nakano M, Bednarczyk JL, et al. Tumor necrosis factor-alpha provokes a hypertrophic growth response in adult cardiac myocytes. Circulation. 1997; 95: 1247-52

38）Krown KA, Page MT, Nguyen C, et al. Tumor necrosis factor alpha- induced apoptosis in cardiac myocytes: involvement of the sphingolipid signalling cascade in cardiac cell death. J Clin Invest. 1996; 98: 2854-65

39）Kubota T, McTiernan CF, Frye CS, et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res. 1997; 81: 627-35

40）Brack KE, Patel VH, Mantravardi R, et al. Direct evidence of nitric oxide release from neuronal nitric oxide synthase activation in the left ventricle as a result of cervical vagus nerve stimulation. J Physiol. 2009; 587: 3045-54

41）Brack KE, Patel VH, Coote JH, et al. Nitric oxide mediates the vagal protective effect on ventricular fibrillation via effects on action potential duration restitution in the rabbit heart. J Physiol. 2007; 583: 695-704

42）Sears CE, Choate JK, Paterson DJ. NO-cGMP pathway accentuates the decrease in heart rate caused by cardiac vagal nerve stimulation. J Appl Physiol. 1999; 86: 510-6

43）Sawyer DB, Colucci WS. Nitric oxide in the failing myocardium. Cardiol Clin. 1998; 16: 657-64

44）Barouch LA, Harrison RW, Skaf MW, et al. Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nature. 2002; 416: 337-9

45）Ziolo MT, Kohr MJ, Wang H. Nitric oxide signaling and the regulation of myocardial function. J Mol Cell Cardiol. 2008; 45: 625-32

46）Champion HC, Skaf MW, Hare JM. Role of nitric oxide in the pathophysiology of heart failure. Heart Fail Rev. 2003; 8: 35-46

47）Umar S, van der Laarse A. Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol Cell Biochem. 2010; 333: 191-201

48）Garrey WE. Some effects of cardiac nerves upon ventricular fibrillation. Am J Physiol. 1908; 21: 283-300

49）Scherf D, Blumenfeld S, Yildiz M. Experimental study on ventricular extrasystoles provoked by vagal stimulation. Am Heart J. 1961; 62: 670-5

50）Harman MA, Reeves TJ. Effects of vagus nerve stimulation on atrial and ventricular function. Am J Physiol. 1968; 215: 1210-7

51）Kolman BS, Verrier RL, Lown B. The effect of vagus nerve stimulation upon vulnerability of the canine ventricle: Role of the sympathetic-parasympathetic interactions. Circulation. 1975; 52: 578-85

52）Zuanetti G, De Ferrari GM, Priori SG, et al. Protective effect of vagal stimulation on reperfusion arrhythmias in cats. Circ Res. 1987; 61: 429-35

53）Vanoli E, De Ferrari GM, Stramba-Badiale M, et al. Vagal stimulation and prevention of sudden death in conscious dogs with a healed myocardial infarction. Circ Res. 1991; 68: 1471-81

54）Bilgutay AM, Bilgutay IM, Merkel FK, et al. Vagal tuning. A new concept in the treatment of supraventricular arrhythmias, angina pectoris, and heart failure. J Thorac Cardiovasc Surg. 1968; 56: 71-82

55）Li M, Zheng C, Sato T, et al. Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats. Circulation. 2004; 109: 120-4

56）Sabbah HN, Ilsar I, Zaretsky A, et al. Vagus nerve stimulation in experimental heart failure. Heart Fail Rev. 2011; 16: 171-8

57）Sabbah HN, Rastogi S, Mishra S, et al. Long-term therapy with neuroselective electric vagus nerve stimulation improves LV function and attenuates global LV remodelling in dogs with chronic heart failure(abstract). Eur J Heart Fail Supplements. 2005; 4(suppl): 166-7

58）Gupta RC, Imai M, Jiang AJ, et al. Chronic therapy with selective electric Vagus nerve stimulation normalizes plasma concentration of tissue necrosis factor-alpha, interleukin-6 and B-type natriuretic peptide in dogs with heart failure (abstract). J Am Coll Cardiol. 2006; 47: 77A

59）Gupta RC, Mishra S, Rastogi S, et al. Chronic therapy with electric Vagus nerve stimulation normalizes mRNA and protein expression of nitric oxide synthase in myocardium of dogs with heart failure (abstract). Eur Heart J. 2006; 27: 477

60）Sabbah HN, Imai M, Zaretsky A, et al. Therapy with Vagus nerve electrical stimulation combined with beta-blockade improves left ventricular function in dogs with heart failure beyond that seen with beta-blockade alone (abstract). Eur J Heart Fail. 2007; 6: 114

61）Zhang Y, Popovic ZB, Bibevski S, et al. Chronic vagus nerve stimulation improves autonomic control and attenuates systemic inflammation and heart failure progression in a canine high-rate pacing model. Circ Heart Fail. 2009; 2: 692-9

62）CardioFit™ for the treatment of heart failure. Available at: http://clinicaltrials.gov/ct2/show/NCT00461019

63）Ben-Menachem E. Vagus nerve stimulation, side effects, and longterm safety. J Clin Neurophysiol. 2001; 18: 415-8

64）Uthman BM, Reichl AM, Dean JC, et al. Effectiveness of vagus nerve stimulation in epilepsy patients, a 12-year observation. Neurology. 2004; 63: 1124-6

65）Schwartz PJ, De Ferrari GM, Sanzo A, et al. Long term vagal stimulation in patients with advanced heart failure: first experience in man. Eur J Heart Fail. 2008; 10: 884-91

66）De Ferrari GM, Crijns HJ, Borggrefe M, et al; CardioFit Multicenter Trial Investigators. Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. Eur Heart J. 2011; 32: 847-55

67）INcrease Of VAgal TonE in CHF (INOVATE-HF). Available at: http://www.clinicaltrials.gov./ct2/show/NCT01303718

68）Hauptman PJ, Schwartz PJ, Gold MR, et al. Rationale and Study Design of the INcrease Of Vagal TonE in Heart Failure Study: INOVATE-HF. Am Heart J. 2012; 163: 954-62

69）Neural Cardiac Therapy for Heart Failure Study (NECTAR-HF). Available at: http://www.clinicaltrials.gov./ct2/show/NCT01385176

70）Autonomic Neural Regulation Therapy to Enhance Myocardial Function in Heart Failure (ANTHEM-HF) Study. Available at: http://www.clinicaltrials.gov./ct2/show/NCT01823887

71）Schwartz PJ, Pagani M, Lombardi F, et al. A cardiocardiac sympathovagal reflex in the cat. Circ Res. 1973; 32: 215-20

72）Shen MJ, Shinohara T, Park HW, et al. Continuous low-level vagus nerve stimulation reduces stellate ganglion nerve activity and paroxysmal atrial tachyarrhythmias in ambulatory canines. Circulation. 2011; 123: 2204-12

73）Lechat P, Hulot J-S, Escolano S, et al; on behalf of the CIBIS II Investigators. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation. 2001; 103: 1428-33

74）Swedberg K, Komajda M, Bohm M, et al; SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010; 376: 875-85

75）Lopshire JC, Zhou X, Dusa C, et al. Spinal cord stimulation improves ventricular function and reduces ventricular arrhythmias in a canine postinfarction heart failure model. Circulation. 2009; 120: 286-94

76）Sabbah HN, Gupta RC, Imai M, et al. Chronic electrical stimulation of the carotid sinus baroreflex improves left ventricular function and promotes reversal of ventricular remodeling in dogs with advanced heart failure. Circ Heart Fail. 2011; 4: 65-70

77）Determining the feasibility of spinal cord neuromodulation for the treatment of chronic heart failure (Defeat-HF). Available at: http://clinicaltrials.gov/ct2/show/NCT01112579

78）Spinal cord stimulation for heart failure (SCS HEART). Available at: http://clinicaltrials.gov/ct2/show/NCT01362725

79）Rheos HOPE4HF trial. Available at: http://clinicaltrials.gov/ct2/show/NCT00957073

80）Barostim neo system in the treatment of heart failure. Available at: http://clinicaltrials.gov/ct2/show/NCT01471860

81）Baroreflex activation therapy in heart failure. Available at: http://clinicaltrials.gov/ct2/show/NCT01484288

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp